Author

Kohichiroh Yasui

Observed names: KOHICHIROH YASUI, Yasui Kohichiroh

Institutions: Kyoto Prefectural University of Medicine, Bukkyo University

Observed institutions: Tokyo Medical and Dental University, Okayama University, Kyoto Prefectural University of Medicine, Japan Science and Technology Agency, Kochi Medical School Hospital, Tokyo Metropolitan Institute of Medical Science, University Hospital Kyoto Prefectural University of Medicine, Bukkyo University

OpenAlex ID: A5110056797

Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis

2014 · Giovanni Musso, Roberto Gambino, et al. · PLoS Medicine · 741

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

2019 · Masatoshi Kudo, Kazuomi Ueshima, et al. · Gut · 724

PDF

Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma

2011 · Kohichiroh Yasui, Etsuko Hashimoto, et al. · Clinical Gastroenterology and Hepatology · 425

The Native Form and Maturation Process of Hepatitis C Virus Core Protein

1998 · Kohichiroh Yasui, Takaji Wakita, et al. · Journal of Virology · 262

Genetic Polymorphisms of the Human PNPLA3 Gene Are Strongly Associated with Severity of Non-Alcoholic Fatty Liver Disease in Japanese

2012 · Takahisa Kawaguchi, Yoshio Sumida, et al. · PLoS ONE · 261

PDF

Alteration in Copy Numbers of Genes as a Mechanism for Acquired Drug Resistance

2004 · Kohichiroh Yasui, Saori Mihara, et al. · Cancer Research · 220

A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease

2010 · Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD), Yoshio Sumida, et al. · Journal of Gastroenterology · 198

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease

2010 · Hyohun Park, Toshihide Shima, et al. · Journal of Gastroenterology · 197

Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease

2008 · Hironori Mitsuyoshi, Kohichiroh Yasui, et al. · Hepatology Research · 184

TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas

2002 · Kohichiroh Yasui, Shigeki Arii, et al. · Hepatology · 171

Nonalcoholic steatohepatitis and increased risk of chronic kidney disease

2010 · Kohichiroh Yasui, Yoshio Sumida, et al. · Metabolism · 161

A Novel Target Gene, SKP2, within the 5p13 Amplicon That Is Frequently Detected in Small Cell Lung Cancers

2002 · Sana Yokoi, Kohichiroh Yasui, et al. · American Journal Of Pathology · 153

PDF

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

2012 · Tokuzo Arao, Kazuomi Ueshima, et al. · Hepatology · 150

PDF

Fenofibrate, a peroxisome proliferator‐activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver

2006 · Yuichi Harano, Kohichiroh Yasui, et al. · Liver International · 149

Amplification and Overexpression of SKP2 Are Associated with Metastasis of Non-Small-Cell Lung Cancers to Lymph Nodes

2004 · Sana Yokoi, Kohichiroh Yasui, et al. · American Journal Of Pathology · 129

PDF

Ptk2 And Eif3s3 Genes May Be Amplification Targets At 8Q23–Q24 and Are Associated With Large Hepatocellular Carcinomas

2003 · Hiroyuki Okamoto, Kohichiroh Yasui, et al. · Hepatology · 117

Transition in the etiology of liver cirrhosis in Japan: a nationwide survey

2019 · Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH, Hirayuki Enomoto, et al. · Journal of Gastroenterology · 109

PDF

Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis

2003 · Chen Zhao, Kohichiroh Yasui, et al. · Cancer · 109

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan

2011 · Takeshi Okanoue, Atsushi Umemura, et al. · Journal of Gastroenterology and Hepatology · 102

PDF

Effect of 12‐week dulaglutide therapy in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease and type 2 diabetes mellitus

2016 · Yuya Seko, Yoshio Sumida, et al. · Hepatology Research · 94

Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitus

2016 · Yuya Seko, Yoshio Sumida, et al. · Hepatology Research · 91

Lower levels of insulin‐like growth factor‐1 standard deviation score are associated with histological severity of non‐alcoholic fatty liver disease

2014 · Yoshio Sumida, Yoshikazu Yonei, et al. · Hepatology Research · 88

Development of hepatocellular carcinoma in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression

2016 · Yuya Seko, Yoshio Sumida, et al. · Hepatology Research · 85

Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease

2015 · Yoshio Sumida, Kazuyuki Kanemasa, et al. · Journal of Gastroenterology · 85

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

2018 · Yuya Seko, Taichiro Nishikawa, et al. · Diabetes Metabolic Syndrome and Obesity · 83

PDF

Works count: 124

Citation count: 7,741

H-index: 49

I10-index: 84